Most Read Articles
Tristan Manalac, 14 May 2020
Liver injuries appear to be more common in severe cases of coronavirus disease 2019 (COVID-19), a new meta-analysis reports.
19 May 2020
Upper respiratory (UR) and atypical symptoms are more likely to occur in children with symptomatic pharyngitis and group A Streptococcus (GAS) on throat culture identified as carrier than those who are acutely infected, according to a study.
16 May 2020
There appears to be no evidence of the SARS-CoV-2 virus in the semen of patients recovering from COVID-19 a month after diagnosis, according to a study, suggesting that the virus is unlikely to gain entry into testicular cells through an ACE2/TMPRSS2-mediated mechanism.
Stephen Padilla, 19 May 2020
Influenza A and B infections show comparable clinical severity in children, a study has shown.

SOF/VEL/VOX safe, effective for rescue hepatitis C treatment

02 Oct 2019

The combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is safe and effective as rescue therapy for hepatitis C patients in whom prior direct-acting antivirals (DAAs) had failed, a new study has found.

Researchers conducted a prospective, multicentre study on 137 patients (median age, 56 years; 75 percent male), who had experienced DAA failure. All participants received 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir contained in a fixed-dose tablet. The primary endpoint was sustained virological response after 12 weeks (SVR 12).

Excluding two patients who were lost to follow-up, 128 of the remaining 135 participants achieved SVR 12. The resulting rate was 95 percent. This was higher in those without cirrhosis, as compared to their cirrhotic counterparts (98 percent vs 89 percent; p=0.05).

SVR 12 rates did not vary according to Child-Turcotte-Pugh scores (p=0.19), the presence of hepatocellular carcinoma (p=0.07), coinfection with HIV (p=0.72) or a history of liver transplant (p=0.66).

On the other hand, 131 participants showed evidence of treatment-related adverse events. Of these, only 25 had mild adverse episodes, most common of which were headaches (36 percent) and asthenia (32 percent). None had to discontinue treatment due to side effects

One patient developed multicentric hepatocellular carcinoma and, after 8 weeks of treatment, had jaundice. The situation worsened quickly and the patient ultimately died before achieving SVR 12.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 14 May 2020
Liver injuries appear to be more common in severe cases of coronavirus disease 2019 (COVID-19), a new meta-analysis reports.
19 May 2020
Upper respiratory (UR) and atypical symptoms are more likely to occur in children with symptomatic pharyngitis and group A Streptococcus (GAS) on throat culture identified as carrier than those who are acutely infected, according to a study.
16 May 2020
There appears to be no evidence of the SARS-CoV-2 virus in the semen of patients recovering from COVID-19 a month after diagnosis, according to a study, suggesting that the virus is unlikely to gain entry into testicular cells through an ACE2/TMPRSS2-mediated mechanism.
Stephen Padilla, 19 May 2020
Influenza A and B infections show comparable clinical severity in children, a study has shown.